Back to Top
Ongericimab Biosimilar - Research Grade
$315.00 - $3,902.00
Ongericimab Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
PCSK9ï؟½
Concentration
5mg/ml
Isotype
IgG4 - kappa
Host
CHO Cells
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Uniprot
Q8NBP7
Shipping Conditions
Blue ice
Background
PCSK9 regulates LDL-receptor turnover and is a well-validated target in lipid-metabolism research. This recombinant human IgG4 kappa antibody is an unconjugated, non-therapeutic analog of ongericimab, expressed in CHO cells against human PCSK9. For research use only, it is purified to a low-endotoxin grade suitable for in vivo studies and supplied in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. It functions as a dependable reagent for PCSK9-blockade assays, receptor-recycling studies, functional readouts, and preclinical models of cholesterol metabolism. Consistent lot-to-lot performance makes it dependable for repeated, large-scale experimentation.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Write Your Own Review













